Header Logo

Connection

BONNIE S GLISSON to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications BONNIE S GLISSON has written about Neoplasm Recurrence, Local.
BONNIE S GLISSON
Connection Strength
0.922
Neoplasm Recurrence, Local
  1. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. 2018 05 15; 124(10):2169-2173.
    View in: PubMed
    Score: 0.171
  2. Recurrent small cell lung cancer: update. Semin Oncol. 2003 Feb; 30(1):72-8.
    View in: PubMed
    Score: 0.060
  3. Treatment of metastatic head and neck cancer: chemotherapy and novel agents. Cancer Treat Res. 2003; 114:295-314.
    View in: PubMed
    Score: 0.059
  4. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 10 15; 26(20):5358-5367.
    View in: PubMed
    Score: 0.050
  5. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clin Cancer Res. 2019 12 01; 25(23):6958-6966.
    View in: PubMed
    Score: 0.047
  6. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
    View in: PubMed
    Score: 0.046
  7. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90.
    View in: PubMed
    Score: 0.043
  8. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017 01; 18(1):42-51.
    View in: PubMed
    Score: 0.039
  9. New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic. Clin Cancer Res. 2015 Sep 01; 21(17):3821-8.
    View in: PubMed
    Score: 0.036
  10. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9.
    View in: PubMed
    Score: 0.035
  11. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013 Jan 29; 8:21.
    View in: PubMed
    Score: 0.030
  12. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):941-7.
    View in: PubMed
    Score: 0.029
  13. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40.
    View in: PubMed
    Score: 0.026
  14. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):399-409.
    View in: PubMed
    Score: 0.022
  15. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):717-24.
    View in: PubMed
    Score: 0.018
  16. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91.
    View in: PubMed
    Score: 0.015
  17. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck. 2002 Jul; 24(7):661-9.
    View in: PubMed
    Score: 0.014
  18. The role of docetaxel in the management of squamous cell cancer of the head and neck. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):83-7.
    View in: PubMed
    Score: 0.014
  19. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002 Mar 15; 20(6):1593-9.
    View in: PubMed
    Score: 0.014
  20. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 01; 92(9):2364-73.
    View in: PubMed
    Score: 0.014
  21. Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma: A single-center retrospective analysis. Head Neck. 2021 12; 43(12):3788-3795.
    View in: PubMed
    Score: 0.014
  22. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591.
    View in: PubMed
    Score: 0.013
  23. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol. 2000 Aug; 27(4 Suppl 8):25-33.
    View in: PubMed
    Score: 0.013
  24. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.
    View in: PubMed
    Score: 0.013
  25. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 04; 1:423-436.
    View in: PubMed
    Score: 0.012
  26. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020 02; 101:104523.
    View in: PubMed
    Score: 0.012
  27. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512.
    View in: PubMed
    Score: 0.011
  28. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30.
    View in: PubMed
    Score: 0.011
  29. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8.
    View in: PubMed
    Score: 0.011
  30. Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb). Am J Clin Oncol. 1991 Oct; 14(5):427-32.
    View in: PubMed
    Score: 0.007
  31. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009 Jun; 32(3):274-9.
    View in: PubMed
    Score: 0.006
  32. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer. 2008 Jun 15; 112(12):2698-709.
    View in: PubMed
    Score: 0.005
  33. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001 Jun 15; 19(12):3010-7.
    View in: PubMed
    Score: 0.003
  34. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001 Apr 01; 91(7):1316-23.
    View in: PubMed
    Score: 0.003
  35. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-33-S19-37.
    View in: PubMed
    Score: 0.003
  36. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):807-11.
    View in: PubMed
    Score: 0.002
  37. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Jun; 12(6):1238-44.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.